Behring Diagnostics looking for a partner ahead of possible flotation of minority stake
This article was originally published in Clinica
Executive Summary
Hoechst, the German pharmaceutical and chemicals group, announced unexpectedly wide-ranging reorganisation plans last week. In 1997, Hoechst will become a strategic management holding, with its entire operating business split into ten legally independent affiliates. One of these will be the company's diagnostics business, Behring Diagnostics. By teaming up with a partner, Hoechst chairman Jurgen Dormann hopes Behring will expand its product range and strengthen its position in America.